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1. Introduction 
Recently,we demonstrated that thrombin-activated 
human platelets express a hemagglutination activity 
not expressed by non-activated platelets and that this 
activity mediates the direct platelet-platelet interac- 
tions which cause platelet aggregation [11. Although 
isolated membranes were found to contain the throm- 
binenhanced hemagglutinin [2], the control of its 
expression wasnot elucidated. In this study, we report 
that the expression of the agglutinin is secretion- 
dependent, caused by secreted materials, and can 
express itself as both a platelet membrane-bound 
entity and a soluble agglutinin, and that the express 
sion of the soluble a~lut~~ is dependent on fibrin 
formation. 
2. Materials and methods 
2 .l . Preparation of platelets 
Blood was drawn in ACD (8.6 ml of blood per 
1.4 ml of acid citrate which contained 2.5 g of Nas- 
citrate.2Hz0, 2 g of glucose and 1 .S g of citric acid 
per 100 ml of HzO). The platelets were washed as 
previously described [ 31. 
2.2. Hemagglu tination assays 
The erythrocytes were prepared and the microtiter 
plate hemagglutination assays were done as previously 
described [2]. Platelets were at 10g{ml. The assays 
using platelets (membrane-bound agglutinin) were 
done in phosphate buffer saline (0.154 M NaCl, 
0.01 M NaP04) at pH 7 .O. The assays using cell-free 
supernatant fractions were done in TCS (0.154 M 
NaCl, 0.01 M Tris, 0.002 M CaC12) at pH 7.4. The 
washed platelets were suspended in ETS (0.001 M 
EDTA,O.Ol MTris,0.154MNaCl,0.2%glucose, 
pH 7 6) for testing. 
3. Results 
3 .l . Secretion dependence 
Thromb~-activated platelets were shown to have a 
greater hema~lutination activity than non-activated 
washed platelets [l]. As a means of determining if 
this increased activity was soluble or membrane-bound, 
activated platelets were removed from suspension by 
centrifugation and the isolated platelets and super- 
natant fractions were tested for agglutinin activity. 
Fig.I shows that resuspended thrombin-activated 
platelets had more activity than the unstimulated 
platelets, but the fraction with the highest specific 
activity was the cell-free supernatant fraction from 
the thrombin-activated platelets. Treatment of platelets 
with prosta~and~ Er(PGEi), a potent inhibitor of 
platelet secretion [4], before exposure to thrombin 
prevented the expression of both platelet bound and 
the soluble agglutinins (fig.1). Addition of PGEt to 
thromb~-activated platelets and the supernatant 
fractions from thrombin-activated platelets did not 
inhibit their agglutinin activities (data not shown), 
Therefore, since an agglutinin activity appears as a 
soluble product following platelet activation and since 
the appearance of all enhanced activity is inhibited by 
an inhibitor of secretion, it seems that the agglutinin 
activities of thromb~-activated platelets are derived 
from secreted materials. 
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Fig.1. Washed platelets in ETS, untreated or treated as 
described, were tested for hemagglutination activity. Platelet- 
free supematant fractions were prepared as follows: Aliquots 
of platelet suspensions in ETS were spun for 30 s in a Beckman 
Microfuge B; the resulting supematant fractions were spun 
for another min; 25 ~1 samples of these supematant fractions 
were tested for hemagglutination activity. Platelets were 
suspended in the original volume of ETS if they were tested 
following centrifugation. PGE, (Upjohn Company) was used 
at a tinal concentration of 10 PM. 
3.2. Soluble a&u tinin activity 
Washed platelets were activated with three other 
stimuli which cause platelet secretion to determine if 
expression of the soluble agglutinin is a unique con- 
sequence of thrombin activation. The other stimuli 
were: (i) y-thrombm [ 51, a hydrolytic product of 
ar-thrombin which has limited proteolytic activity; 
(ii) the Ca*’ ionophore A23187 [6] ; and (iii) throm- 
bocytin, a serine protease isolated from snake venom 
[7,8]. The cell-free supernatant fractions derived 
from platelets activated by y-thrombin or A23187 
had no hemagglutinin activity and the comparable 
fractions from thrombocytin activated platelets had 
only slight activity (fig.2). Since all these agents 
caused secretion, it seems that secretion, per se, is 
not sufficient for the expression of the soluble agglu- 
tinin. Rather, it appears that the secreted materials 
have to be activated by cu-thrombin before they 
express agglutinin activity. 
As a test of this hypothesis, the inactive super- 
natant fractions described above were treated with 
a-thrombin and assayed for agglutinin activity. Fig.2 
shows that cu-thrombin produced agglutinin activity 
in the previously inactive preparations. PMSF 
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Fig.2. Washed platelets were in ETS unless otherwise stated. 
The platelets were tested directly or after the treatments 
described. Washed platelets treated with ADP were in Tyrode 
buffer. *Washed platelets were exposed to 0 5 U/ml of human 
thrombin (a generous gift of Dr John Fenton) for 1 mm 
before testing or fractionation. Thrombinactivated platelets 
and the cell-free supernatant fraction of the activated platelets 
were treated with 20 wg/ml final concentration of trypsin and 
incubated at room temperature for 15 min, the reaction was 
halted by 200 I.rg/ml (final concentration) of soy bean trypsin 
inhibitor. Controls were treated with a trypsin preparation 
previously incubated with a soy bean trypsin inhibitor. Washed 
platelets were activated with 5 PM ADP, or a 2 PM concentra- 
tion of A23187, or 5 fig/ml of r-thrombin (a generous gift of 
Dr John Fenton), or 5 rg/ml of thrombocytin (a generous gift 
of Dr Stefan Niewiarowski). The cell-free supernatant frac- 
tions were derived from duplicate samples of these prepara- 
tions and were activated with 0.5 U/ml of thrombin. Cell-free 
supernatant fractions from nonstimulated platelets occasion- 
ally had slight agglutination activity, however, in most cases 
these fractions had no activity. tAJ1 enhanced hemagglutina- 
tion activities were inhibited by 30 mM arginine, galactos- 
amine, glucosamine, mannosamine, but not by glutamine, 
galactose, glucose, mannose, and the Nacetylated derivatives 
of the amino sugars at the same concentration. 
inactivated ar-thrombm [9] was without effect and 
cr-thrombin itself did not agglutinate the fixed erythro- 
cytes (data not shown). These results demonstrate 
that cY-thrombin has at least two functions in gener- 
ating the soluble agglutinin activity: it causes secre- 
tion and subsequent activation of the molecules 
which acquire agglutinin activity. 
Since a-thrombin activated the soluble, cell-free 
secreted materials, but y-thrombin had no effect and 
thrombocytin had only a slight effect, it may be that 
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the differences in the proteolytic specificities of these 
enzymes account for this behavior. A fundamental 
functional difference between these enzymes is that 
ar-thrombin can readily cleave the fibrinopeptides A 
and B from the (Y and P-chains of fibrinogen, a pro- 
tein secreted by platelets during activation [lo], where- 
as, y-thrombin and thrombocytin have very limited 
ability to catalyze these reactions [5-71. Therefore, 
the ability of a-thrombin to activate the secreted 
materials and thereby generate soluble agglutinin 
activity may be due to the production of fibrin from 
secreted fibrinogen. 
Fig.3 shows the effect of a-thrombin on the 
hemagglutination activity of fibrinogen. Fibrinogen 
at 0.5 mg/ml did not agglutinate the fixed erythro- 
cytes. Addition of ADP, y-thrombin or thrombocytin 
to the fibrinogen caused no activation of its hemag- 
glutination activity. In contrast, treatment of fibri- 
nogen with 0.5 U/ml of cu-thrombin resulted in activa- 
tion of the hemagglutination activity. This fibrin- 
caused agglutination was inhibited by 30 mM arginine, 
mannosamine, glucosamine, and galactosamine, but 
not by glutamine, mannose, glucose, galactose, lactose, 
or the N-acetylated derivatives of the amino sugars. 
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Fig.3. Fibrinogen hemagglutination assays were done in TCS. 
25 ~1 samples of the test substances were evaluated for 
activity. Fibrinogen (Kabi, Grade L) was at 0.5 mg/ml, ADP 
at 5 PM, -y-thrombin at 5 pg/ml, thrombocytin at 5 pg/ml 
and o-thrombin at 0.5 U/ml in the test mixtures. *This 
fibrincaused agglutination was inhibited by a final concen- 
tration of 30 mM arginine, mannosamine, glucosamine, and 
galactosamine, but not by glutamine, mannose, glucose, 
galactose, lactose, or the Nacetylated derivatives of the 
amino sugars at the same concentration. 
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3.3. Platelet-bound agglutirzirl activio 
Fig.2 shows the requirements for the expression of 
platelet bound enhanced hemagglutination activity. 
Discoid, washed platelets (the suspensions were 
birefringent) suspended in Tyrode solution at 37°C 
were tested for enhanced hemagglutination activity 
following shape change caused by ADP. Shape change 
caused by ADP under these conditions does not result 
in secretion [ 111. The non-discoid (shape-changed) 
platelets lacked both enhanced hemagglutination 
activities (fig .2). In contrast, washed platelets 
suspended in ETS (EDTA is required to prevent 
platelet aggregation) and treated with the Ca’+ iono- 
phore A23 187, y-thrombin or thrombocytin had 
enhanced platelet bound hemagglutination activity. 
In view of these results and the fact that PGE, (fig.1 
and [2]) treatment of platelets prevents expression of 
the platelet-bound thrombinenhanced hemagglutina- 
tion activity, it is clear that expression of this activity 
is not caused simply by either shape change or prote- 
olysis of the platelet surface by thrombin, but is 
secretiondependent. In contrast to the soluble 
agglutinin, its expression is not dependent on the 
presence of a-thrombin. 
4. Discussion 
The results presented here demonstrate that the 
expression of the hemagglutination activity derived 
from washed platelets is secretiondependent and can 
manifest itself in two ways: as platelet-bound enhanced 
hemagglutination activity and as the soluble agglutina- 
tion activity of activated cell-free supernatant frac- 
tions derived from activated platelets. In both cases, 
activation of the platelets causes secretion of mole- 
cules which mediate agglutination. Platelet-bound 
enhanced hemagglutination activity is caused by 
secreted molecules cross-linking activated platelets to 
fixed erythrocytes. This type of hemagglutination is 
not dependent on exogeneous protease activity for its 
expression. In contrast, the soluble agglutinin activity 
of cell-free supernatant fractions from activated 
platelets requires activation by an exogeneous protease 
for its expression. This type of hemagglutination 
activity is caused by bridging molecules which cross- 
link the fixed erythrocytes. In both cases, cell-cell 
interactions are caused by the attachment of secreted 
molecules to the surfacesof the interacting cells. Both 
of these agglutinin activities are inhibited by the same 
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compounds which inhibit platelet aggregation induced 
by thrombin or ADP and fibrinogen. 
The molecules which cause these agglutinin activi- 
ties have not been identified.However, these activities 
appear to be dependent on secreted proteins since 
trypsin inactivates both activities (fig.2 and [ 1;2J). 
The agglutinin activities are not caused solely by 
secreted ADPand fibrinogen because the fixed erythro- 
cytes used in this study cannot be agglutinated by 
these compounds. However, the results of fibrinogen 
treatment with ar-thrombin vs. y-thrombin and throm- 
bocytin demonstrate that the expression of the cell- 
free a~iut~in activity is dependent on fibrin forma- 
tion. This conclusion does not mean, however, that 
other secreted substances do not participate in 
mediating the agglutination caused by the activated 
cell-free supernatant fractions. The results with the 
platelet-bound enhanced hemagglutinin activity 
demonstrates that its expression is caused by secreted 
substances and is not dependent on fibrin formation. 
Therefore, since ADP and ~br~ogen cannot agglut~ate 
the fixed red cells, this platelet-bound activity is 
caused by secreted substances other than, but not 
necessarily excluding, ADP and fibrinogen. 
Regardless of how the enhanced agglutinin activi- 
ties were generated, all those activities described here: 
the soluble (fig.2) the platelet-bound (fig.2) and even 
that caused by treatment of fibrinogen with cr-throm- 
bin (fig.3), were inhibited by the same concentrations 
of the same compounds which inhibited the hemag- 
glutination activity of isolated platelet membranes [2], 
and aggregation of platelets induced by thrombin or 
ADP and fibrinogen [ l]. Since all these activities are 
inhibited by the same compounds, they are probably 
mediated by a common molecular entity, 
These results suggest hat secreted materials other 
than ADP and fibrinogen play a role in platelet aggre- 
gation. It is known that washed platelets in Tyrode 
solution containing fibrinogen aggregate in response 
to ADP [ 121. Furthermore, it is known that damaged 
red cells release ADP and that plasma contains a high 
concentration fibrinogen ] 13,141. Thus, ADP and 
~br~nogen mediated aggregation can occur in the 
absence of thrombin and is not dependent on secreted 
materials [ 111. Therefore, in view of the results 
presented here, there may be at least two distinct 
mechanisms for mediating platelet aggregation: one 
mechanism (exogeneous ADP and fibrinogen) which 
is dependent on neither thrombin nor platelet-secreted 
materials, and another mechanism which is dependent 
on both thrombin and secreted substances. 
The control of expression of cell agglutinins or 
their receptors by secretion is not an exclusive feature 
of platelets. For example, preliminary studies with the 
cellular slime molds ~~c~os~~~i~rn dis~~~~u~~ and 
Polyspholldyliumpal~idum suggest hat the expression 
of their developmentally controlled receptors for the 
lectins thought to mediate aggregate formation by 
cohesive amoebae may also be controlled by a secre- 
tion mechanism [ 15 ,161. Likewise, the aggregation of 
marine sponge cells is mediated by a complex extra- 
cellular aggregation factor [ 17 ,181 which may be 
released by secretion. Thus, secretion may be an 
ancient means of controlling the expression of specific 
cell agglutinins. These facts raise the possibility that a 
variety of metazoan cell types may use secretion as a 
method for controlling the expression of cell agglutinins 
or their receptors. 
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